Abstract
It can be argued that little has changed in treatment of type 1 diabetes in children and adolescents for more than 80 years: there have been new ways to produce insulin, better ways to monitor insulin, and new devices to administer insulin. However, the treatment of type 1 diabetes in pediatrics is still solely based on administration of insulin. In this chapter, we will review the limitations of insulin extracted from animal pancreases and the impact of the ability to produce biosynthetic human insulin. This has led to the production of rapid- and long-acting insulin analogs and the further development of ultra-rapid and long-acting insulin preparations. Adjunctive therapies for type 1 diabetes are discussed in Chap. 13.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Bliss M. Banting’s, Best’s, and Collip’s accounts of the discovery of insulin. Bull Hist Med. 1982;56:554–68.
Scott DA. Crystalline insulin. Biochem J. 1934;1592-1602(1591):28.
Howey DC, Bowsher RR, Brunelle RL, Woodworth JR. [Lys(B28), Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin. Diabetes. 1994;43:396–402.
Lindholm A, McEwen J, Riis AP. Improved postprandial glycemic control with insulin aspart. A randomized double-blind cross-over trial in type 1 diabetes. Diabetes Care. 1999;22:801–5.
Mudaliar SR, Lindberg FA, Joyce M, et al. Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. Diabetes Care. 1999;22:1501–6.
Swan KL, Dziura JD, Steil GM, Voskanyan GR, Sikes KA, Steffen AT, Martin ML, Tamborlane WV, Weinzimer SA. Effect of age of infusion site and type of rapid-acting insulin analog on the pharmacodynamic and pharmacokinetic parameters in youth with T1DM on insulin pump therapy. Diabetes Care. 2009;32:240–4.
Heinemann L, Sinha K, Weyer C, Loftager M, Hirschberger S, Heise T. Time-action profile of the soluble, fatty acid acylated, long-acting insulin analogue NN304. Diabet Med. 1999;16:332–8.
Cengiz E, Swan KL, Tamborlane WV, Sherr JL, Fredericksen-Martin M, Weinzimer SA. The alteration of Aspart insulin pharmacodynamics (PD) when mixed with Detemir insulin. Diabetes Care. 2012;35:690–2.
Heise T, Korsatko S, Nosek L, et al. Steady state is reached within 2-3 days of once-daily administration of degludec, a basal insulin with an ultralong duration of action. J Diabetes. 2016;8:132–8.
Elahi S, Patel A, Guandalini C, Steffen A, Sherr J, Tamborlane WV, Van Name M. Impact of switching youth with diabetes to insulin degludec in clinical practice. Endocr Pract. 2019;25:226–9.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Cengiz, E., Van Name, M., Tamborlane, W.V. (2021). Insulin Treatment of Type 1 Diabetes. In: Tamborlane, W.V. (eds) Diabetes in Children and Adolescents. Contemporary Endocrinology. Humana, Cham. https://doi.org/10.1007/978-3-030-64133-7_5
Download citation
DOI: https://doi.org/10.1007/978-3-030-64133-7_5
Published:
Publisher Name: Humana, Cham
Print ISBN: 978-3-030-64132-0
Online ISBN: 978-3-030-64133-7
eBook Packages: MedicineMedicine (R0)